Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

Ashraf RedaAhmed Shawky ElserafyElsayed FaragTamer MostafaNabil FaragAtef ElbahryOsama SanadAhmed BendaryAhmed ElkershMohammed SelimMorad BeshayHazem Khamis

Published in: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2020)

We recommend the use of PCSK9 inhibitors in addition to statins ± ezetimibe in patients with ASCVD, by definition at very high risk; patients with ASCVD at very high risk who do not tolerate appropriate doses of at least three statins; and familial hypercholesterolaemia patients with clinically diagnosed ASCVD, at very high cardiovascular risk.

Keyphrases

low density lipoprotein
cardiovascular disease
early onset
clinical practice
type diabetes